Data for Cross-platform Construction of Comprehensive Proteomic Database for Human Corneal Epithelial Cell
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Epithelial Cell, Cell Culture
SUBMITTER: 
Jimmy Ka-wai Cheung
LAB HEAD: Thomas Chuen Lam
PROVIDER: PXD059451 | Pride | 2025-03-24
REPOSITORIES: Pride
Dataset's files
Items per page: 5 1 - 5 of 140 |
Similar Datasets
Project description:Comprenhensive proteomic analysis of HCEC using Trapped Ion Mobility Spectrometry Time-of-Flight Pro2, Orbitrap Fusion Lumos and ZenoTrap Time-of-Flight 7600 Mass Spectrometer
2024-11-03 | PXD055275 | Pride
Project description:Globally, over 65 million individuals are estimated to suffer from post-acute sequelae of COVID-19 (PASC). A large number of individuals living with PASC experience cardiovascular symptoms (i.e. chest pain and heart palpitations) (PASC-CVS). The role of chronic inflammation in these symptoms, in particular in individuals with symptoms persisting for >1 year after SARS-CoV-2 infection, remains to be determined. Here, we show that compared to individuals with a resolved SARS-CoV-2 infection (and no persistent symptoms), individuals with prolonged PASC-CVS had elevated levels of pro-inflammatory cytokines. However, these cytokines were found to be present in trace amounts, such that they could only be detected with the use of novel nanotechnology. Importantly, these trace-level cytokines had a direct effect on the functionality of primary human cardiomyocytes in vitro. Proteomics analyses demonstrated further differences in PASC-CVS and recovered plasma including increased abundance of complement and coagulation associated proteins.
2024-11-01 | PXD050202 | Pride
Project description:Chondrogenesis, the process through which cartilage forms, has implications for cartilage repair and osteoarthritis (OA) management. In this study, we present the first comprehensive quantitative analysis of the surfaceome of chondrogenic cells using a well-established in vitro chondrogenic model. By employing glycocapture-assisted enrichment targeting sialic acid residues on surface proteins, combined with high-throughput shotgun mass spectrometry, we identified novel components of the chondrogenic cell surfaceome.
2026-01-19 | PXD064013 | Pride
Project description:The sarcomagenic process initiates upon the tumoral transformation of mesenchymal stromal/stem cell (MSCs) or MSC-derived cell types. Experimental evidence also supports that sarcoma evolution is in part driven by the emergence of subpopulations of cancer stem cells (CSCs) after the accumulation of further epigenetic and/or genetic alterations. These CSCs are strongly associated with the evolution of tumors towards more aggressive behaviors. Therefore, the characterization of these subpopulations will contribute to develop more effective therapies against these tumors. With this aim, we used tandem mass spectrometry to the compare the proteome of adherent and CSC-enriched tumorsphere cultures in a tumor progression model of myxoid liposarcoma composed by three cell lines showing increasing aggressiveness after being serially transplanted in mice. In this analysis we found that the expression of the antioxidant enzyme GPX1 increased constantly during the CSC-enrichment process in all the cell lines of the model. Depletion of GPX1 resulted in decreased proliferation, tumorsphere-forming potential and migration capability in vitro and dramatically reduced tumor-formation ability in vivo. Conversely, GPX1 overexpression resulted in increased in vivo tumorigenicity. In agreement with this findings, GPX1 expression in sarcoma patients was associated to advanced tumor stages, more aggressive phenotypes, and a worse prognosis. A proteomic analysis showed that these functional effects were associated with a downregulation of interferon-mediated response, the IL6/JAK/STAT3 axis and the NFκB-mediated signaling in GPX1-silenced cells. Overall, these results suggest that this factor may be a functional marker of aggressive CSCs subpopulations in sarcoma with prognostic and therapeutic implications.
2025-10-20 | PXD052595 | Pride
Project description:The origin of aberrant DNA methylation in cancer remains largely unknown. In this study, we elucidated the DNA methylome in primary Acute Promyelocytic Leukemia (APL) and the role of PML-RARa in establishing these patterns. APL patients showed increased genome-wide DNA methylation with higher variability than healthy CD34+ cells, promyelocytes and remission bone marrow. A core set of differentially methylated regions in APL was identified. Age at diagnosis, Sanz score and Flt3-mutation status characterized methylation subtypes. Transcription factor binding sites, e.g. c-myc binding sites were associated with low methylation. SUZ12 and REST binding sites identified in embryonic stem cells were, however, preferentially DNA hypermethylated in APL. Unexpectedly, PML-RARa binding sites were also protected from aberrant DNA methylation in APL. In line, myeloid cells from pre-leukemic PML-RARa knock-in mice did not show altered DNA methylation and expression of PML-RARa in hematopoietic progenitor cells prevented differentiation without affecting DNA methylation. ATRA treatment of APL blasts did also not result in DNA methylation changes. These results suggest that aberrant DNA methylation is associated with leukemia phenotype but not required for PML-RARa-mediated initiation of leukemogenesis. We used Reduced Representation Bisulfite Sequencing (RRBS) to determine the genome-wide methylation signature of 18 primary APL patient samples. We then compared the APL methylation signature with methylation patterns found in CD34+ progenitor cells (n=4), promyelocytes (n=4) and remission bone marrow samples (n=8). Differentially methylated regions found in all three comparisons (APL vs. all three control specimens) were then further analyzed for genomic localization, variability and association with clinical parameters. Finally, the relationship between differentially methylated regions in APL and specific transcription factor binding sites was analyzed. For this purpose, ChiP-Sequencing of SUZ12 and REST was performed in primary APL patient blasts. To further determine the contribution of the leukemogenic transcription factor PML-RARa to methylation in APL, we also performed RRBS in pre-leukemic PML-RARa knock-in mice and hematopoetic progenitor cells retrovirally transduced with PML-RARa.
2012-11-08 | E-GEOD-42044 | biostudies-arrayexpress
Project description:Identifying children at risk of developing asthma is crucial in guiding targeted preventive therapies. In recent years, researchers have proposed several candidate biomarkers for predicting AM. One such biomarker is fatty-acid-binding protein 5 (FABP5), which correlates with interleukin-17A levels in both the skin and serum, suggesting its potential as a biomarker for AM. Specific IgE, skin prick tests, and cytokine ratios show promise in predicting asthma development.3 However, while these proposed biomarkers are the subject of research on the skin, no biomarkers are identified through blood proteomics. Although AD may initially result from skin barrier dysfunction, systemic sensitization and changes in systemic immune response may predominantly contribute to asthma after AD. Therefore, this study aims to identify blood biomarkers in early life to predict AM progression among infants initially diagnosed with AD. The study participants included 20 healthy controls, 15 with AD, 11 with asthma, and 21 with AM (children aged 7 years old). All participants were diagnosed with asthma, and a history of AD was confirmed by a physician. The protein expression profiles in plasma samples collected from 3-year-olds before the onset of AM were evaluated using sequential window acquisition of all theoretical mass spectra.
2025-05-06 | PXD050231 | Pride
Project description:This SuperSeries is composed of the following subset Series: GSE42044: DNA methylation changes are a late event in Acute Promyelocytic Leukemia and coincide with loss of transcription factor binding (sequencing) GSE42118: DNA methylation changes are a late event in Acute Promyelocytic Leukemia and coincide with loss of transcription factor binding (Illumina Methylation) Refer to individual Series
2012-11-08 | E-GEOD-42119 | biostudies-arrayexpress
Project description:Mechanical thrombectomy (MT) has improved disability outcomes after ischemic stroke (IS), mainly when the so-called modified first-pass effect (mFPE) is achieved. This study aims to explore the proteomic profiling of thrombi composition in those patients who achieved mFPE. A prospective study was conducted based on consecutive IS patients who underwent MT for proteomic analysis of the thrombi, comparing whether the mFPE was achieved or not. A qualitative and quantitative protein analysis was performed using LC-MS/MS for DDA and SWATH-MS analysis, respectively. Dysregulated proteins were considered when the range p-value <0.05, and a fold change >1.5 (upregulated) or <0.6 (downregulated). A total of 88 patients were included, with a median age of 75 years (±16) and 55.7% females (49 patients). mFPE was presented in 48.9% (43 patients), and showed better functional independence at 90 days (62.2% vs. 37.8%; p=0.02). Proteomic qualitative DDA analysis showed 9 dysregulated proteins, while quantitative SWATH-MS analysis found 79 dysregulated proteins, both for patients who achieved mFPE (ACTN1, ACTN4, ANXA1, HSP90AB1, HSP90B1, PPBP, HBA1, FLNA, TLN1, SCPEP1, LGALS1, ADAP1, ITGB3, and S100A9). The most relevant biological pathways involved were endothelial dysfunction, platelet dysfunction, atheromatosis, and inflammation. This proteomic study provides new insights into the biological complexity of IS, revealing distinct protein expression patterns, particularly in those who achieved the mFPE, and may serve as potential biomarkers for prognostication and therapeutic targeting.
2026-03-30 | PXD066161 | Pride
Project description:The CEBPA transcription factor is frequently mutated in acute myeloid leukemia (AML). Mutations in the CEBPA gene, which are typically biallelic, result in the production of a shorter isoform known as p30. Both the canonical 42-kDa isoform (p42) and the AML-associated p30 isoform bind chromatin and activate transcription, but the specific transcriptional programs controlled by each protein and how they are linked to a selective advantage in AML is not well understood. Here, we show that cells expressing the AML-associated p30 have reduced baseline inflammatory gene expression and display altered dynamics of transcriptional induction in response to LPS, consequently impacting cytokine secretion. This confers p30-expressing cells an increased resistance to the adverse effects of prolonged exposure to inflammatory signals. Mechanistically, we show that these differences primarily result from the differential regulation of AP-1 family proteins. In addition, we find that the altered function of the AP-1 member ATF4 in p30-expressing cells alters their response to ER stress. Collectively, these findings uncover a novel link between mutant CEBPA, inflammation and the stress response, potentially revealing a new vulnerability in AML.
2025-03-13 | PXD053800 | Pride
Project description:Age-related bone degeneration is driven by structural deterioration, chronic inflammation, and impaired regenerative capacity, leading to an increased incidence of osteoarticular disorders. Mesenchymal stromal/stem cells (MSCs) have emerged as promising therapeutic candidates due to their immunomodulatory and regenerative properties, mediated largely through their secretome and extracellular vesicles (EVs). However, the therapeutic efficacy of MSC-derived products depends on both the cell source and the conditioning stimuli to which MSCs are exposed. In this study, we performed a comparative proteomic and exosomal microRNA (miRNA) profiling of secretomes derived from placenta-derived MSCs (PSCs) and adipose-derived MSCs (ASCs), and assessed the impact of priming strategies, including hypoxia, interferon-gamma (IFNγ), and interleukin-1 beta (IL1β), on paracrine properties of these cells. Proteomic analysis identified over 7,000 proteins, with PSC secretome enriched in pathways related to osteogenesis, chondrogenesis, extracellular matrix organization, angiogenesis, and immune regulation, whereas ASC secretome displayed limited enrichment in these processes. Functional scoring highlighted IL1β priming as the most effective strategy to enhance osteochondral and immunomodulatory protein signatures in PSCs. Differently, IFNγ priming selectively expanded the repertoire of exosomal miRNAs, with enrichment in signaling networks including Wnt/β-catenin, TGF-β, NF-κB, and T cell receptor pathways, underscoring its role in fine-tuning immune and regenerative functions. Together, these findings reveal that PSCs secrete a broader and more functionally relevant spectrum of bioactive molecules for osteoarticular applications compared with ASCs. Moreover, distinct priming strategies can differentially modulate their paracrine outputs. IL1β primarily enhances protein-driven regenerative and immunomodulatory activity, whereas IFNγ promotes a functionally enriched exosomal miRNA cargo. These results support PSC-derived secretomes as versatile candidates for next-generation, cell-free therapies in osteoarticular disease.
2026-06-15 | PXD068866 | Pride